Literature DB >> 29438360

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.

A Linton1, Y Y Cheng1, K Griggs2, L Schedlich1, M B Kirschner1, S Gattani1, S Srikaran1, S Chuan-Hao Kao1, B C McCaughan3, S Klebe2, N van Zandwijk1, G Reid1.   

Abstract

This corrects the article DOI: 10.1038/bjc.2017.85.

Entities:  

Year:  2018        PMID： 29438360      PMCID： PMC5908673          DOI： 10.1038/bjc.2018.3

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


Correction to: British Journal of Cancer (2014) 110, 510–519; doi:10.1038/bjc.2013.731; published online 10 December 2013 The name of the fourth author was omitted. The author is Lyn Schedlich, and all the author names and affiliations are shown correctly above. This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.
  2 in total

1.  shRNA targeting PLK1 inhibits the proliferation and invasion of nasopharyngeal carcinoma cells.

Authors:  Yan Zhou; Chu Wu; Bingxue Liu; Juan Zhu; Yating Zhong; Yuqing Yuan; Yue Huang; Yunlian Tang
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

2.  Identification of CDK1 as a candidate marker in cutaneous squamous cell carcinoma by integrated bioinformatics analysis.

Authors:  Si Qin; Yu Yang; Hao-Bin Zhang; Xiao-Huan Zheng; Hua-Run Li; Ju Wen
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.